PK MED Secures €1.5M in Financing for Groundbreaking Cell-Homing Technology

PK MED receives €1.5M in DeepTech Financing

PK MED (Linkedin), a Lyon-based biotechnology company, has secured €1.5M in non-dilutive financing to accelerate the development of their cell-homing technology, PKM-02. This technology aims to enhance bone marrow transplantation for patients with diseases like leukemias and hemoglobinopathies.

Funding Amount: €1.5 million

Industry: Medical Equipment Manufacturing

Employee Count: 1001-5000

CEO: Sheri Dodd (CEO Linkedin)

What PK MED needs to buy: PK MED is seeking collaborations with research organizations, manufacturers, and clinical trial support services. Companies specializing in bone marrow transplantation, cell-homing technologies, manufacturing of therapeutic implants, and clinical studies can be valuable partners for PK MED's ambitious development goals in the medical field.